Results 191 to 200 of about 143,588 (347)

The ‘Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease’ (PATROL) study

BJU International, EarlyView.
Background Inherited (germline) pathogenic and likely pathogenic variants (gPVs) in key genes associated with increased risk of prostate cancer (PCa) now warrant more attentive PCa screening per National Comprehensive Cancer Network (NCCN) guidelines—e.g., BRCA2, HOXB13, ATM, BRCA1, MSH2, MSH6, CHEK2 and TP53.
Heather H. Cheng, Kara N. Maxwell, Keyan Salari, Matthew R. Cooperberg, Kristin Follmer, Joanne M. Jeter, Grace Jun, Daniel J. Lee, Hiten D. Patel, Edward M. Schaeffer, Alexandra O. Sokolova, Erika M. Wolff, Daniel W. Lin   +12 more
wiley   +1 more source

Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy

Nature Cancer, 2020
R. Samstein, C. Krishna, Xiaoxiao Ma, X. Pei, Ken-Wing Lee, V. Makarov, F. Kuo, J. Chung, Raghvendra M Srivastava, T. Purohit, Douglas R. Hoen, Rajarsi Mandal, J. Setton, Wei H. Wu, Rachna Shah, B. Qeriqi, Q. Chang, S. Kendall, L. Braunstein, B. Weigelt, Pedro Blecua Carrillo Albornoz, L. Morris, D. Mandelker, J. Reis-Filho, E. de Stanchina, S. Powell, T. Chan, N. Riaz   +27 more
semanticscholar   +1 more source

A BRCA1- és BRCA2- asszociált örökletes emlő- és petefészek tumorok genetikai vizsgálata a Debreceni Egyetemen

Az örökletes emlő- és petefészek tumor szindrómák 50%-ában mutatható ki a BRCA1 vagy a BRCA2 gének csírasejtes mutációja. 2019-2022 között a Debreceni Egyetem Klinika Központ (DE KK) Laboratóriumi Medicinában 951 egyén esetén történt meg a BRCA1/2 gének
Majoros, Viktória
core  

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Five Decades of Innovation—Tailored Breast Cancer Treatment: 1976–2026

World Journal of Surgery, EarlyView.
Ipshita Prakash, Pooja Ramakant, Sandra Krishnan, Sharon W. W. Chan, Tadahiko Shien, Kavitha Daester, Michael Douek, Mee Hoong See, Jacqueline Jeruss, Cheng‐Har Yip, Ines Buccimazza   +10 more
wiley   +1 more source

Targeting Cell Cycle Vulnerabilities in Cancers: Emerging Strategies for Therapeutic Development

Cancer Science, EarlyView.
Dysregulated cell cycle control often involves alternative compensatory pathways in cancers to maintain its robustness but provide unique targetable vulnerabilities. We overview recent insights on cancer‐specific vulnerabilities across the cell cycle and discuss how these can be used to develop new therapeutic strategies.
Nana Kamakura, Minji Jo, Motoko Takahashi, Toru Hirota   +3 more
wiley   +1 more source

NTAQ1 Promotes Hepatocellular Carcinoma Growth by Facilitating the Protein Degradation of the Tumor Suppressor PRDM2

Cancer Science, EarlyView.
Copy number variation analysis in The Cancer Genome Atlas identified NTAQ1 as a potential driver of HCC progression. NTAQ1 accelerates tumor growth by promoting the degradation of the tumor suppressor protein PRDM2, thereby impairing DNA repair and suppressing apoptosis. These findings indicate that NTAQ1 could be a valuable target for the treatment of
Tomohiko Ikehara, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Masahiro Hashimoto, Yusuke Nakano, Katsushi Dairaku, Yuya Ono, Yuki Miyata, Chihiro Matsumoto, Takanari Tatsumi, Satoshi Higuchi, Takashi Ofuchi, Akinori Tsujimoto, Yuki Ando, Qingjiang Hu, Yusuke Yonemura, Akira Shimizu, Takaaki Masuda, Yuji Soejima, Koshi Mimori   +21 more
wiley   +1 more source

Evaluation of healthcare management issues in the provision of clinical services for familial breast/ovarian cancer

, 2009
Electronic version does not contain associated previously published materialDespite there being pragmatic national guidelines for assigning risk to women with a family history of breast cancer, the evidence base is still sparse.
de Azevedo Moreira Reis, Marta
core  

Genetic Evolution in BRCA1‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis

Cancer Science, EarlyView.
Multi‐region sequencing of 57 BRCA1‐associated breast cancers identified TP53 as the dominant initial driver, defining a triple‐negative subgroup with biallelic BRCA1 loss and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers and linked to reduced HRD, EMT activation, and a trend toward worse survival.
Li Hu, Zhongwu Li, Qiting Wan, Xingyu Liao, Yaxin Zhang, Qian Liu, Xinyun Ding, Hua Meng, Yifan Wu, Jie Sun, Juan Zhang, Lu Yao, Ye Xu, Yuntao Xie   +13 more
wiley   +1 more source